Outbreak of Bacille Calmette-Guérin-related lymphadenitis in Saudi children at a university hospital after a change in the strain of vaccine

Annals of Saudi Medicine

Volumn 32, Issue 1, 2012, Pages 4-8

  Alrabiaah, Abdulkarim Abdullah ^a   Alsubaie, Sarah Suliman ^a,b   Bukhari, Elham Issa ^a   Gad, Ashry ^a   Alzamel, Fahad Abdullah ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; ISONIAZID; RIFAMPICIN;

ARTICLE; BACTERIAL STRAIN; BCG VACCINATION; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INFANT; LYMPHADENITIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SAUDI ARABIA; TUBERCULOSIS; TUBERCULOSIS CONTROL; UNIVERSITY HOSPITAL; CLASSIFICATION; EPIDEMIC; ISOLATION AND PURIFICATION; MYCOBACTERIUM BOVIS; NEWBORN; SUPPURATION;

BCG VACCINE; DISEASE OUTBREAKS; FOLLOW-UP STUDIES; HOSPITALS, UNIVERSITY; HUMANS; INFANT; INFANT, NEWBORN; LYMPHADENITIS; MYCOBACTERIUM BOVIS; RETROSPECTIVE STUDIES; SAUDI ARABIA; SUPPURATION; TUBERCULOSIS;

EID: 84857178677     PISSN: 02564947     EISSN: 09754466     Source Type: Journal    
DOI: 10.5144/0256-4947.2012.4     Document Type: Article

References (26)

1. Lugosi L. Theoretical and methodological aspects of BCG vaccine from the discovery of Calmette and Guerin to molecular biology. A review. Tuber Lung Dis 1992;73:252-61
2. Grange JM, Gibson J, Osborn TW, Collins CH, Yates MD. What is BCG ? Tubercle 1983; 64 : 129-39.
3. Bannon MJ. BCG and tuberculosis. Arch Dis Child 1999;80:80-3.
4. Behjati M, Ayatollahi J. Post BCG lymphadenitis in vaccinated infants in Yazd, Iran. Iran J Pediatr 2008; 18: 351-6
5. Milstien JB, Gibson JJ. Quality control of BCG vaccine by WHO : a review of factors that my influence vaccine effectiveness and safty. Bull WHO 1990;58:93-108
6. Goraya JS, Virdi VS, Bacilli calmette-guerin lymphadenitis. Postgraduate Med J London. 2002; 78(920) :327-9.
7. Goraya JS, Virdi VJS. Treatment of BCG -lymphadenitis -a meta-analysis. Pediatr Infect Dis J 2001;20:632-4
8. World Health Organization. BCG -the current vaccine for tuberculosis [Internet]. World Health Organization. C 2011 [cited 2011 Mar 5]. Available from: http://www.who.int/vaccine-research/diseases/tb/vaccine-development/bcg/ en/
9. Aziz MA, Wright A. The World Health Organization/International Union against tuberculosis and lung disease global project on surveillance for antituberculosis drug resistance: a model for other infectious diseases. Clin Infect Dis 2005;41:258 -62.
10. Al-Hajoj SA. Tuberculosis in Saudi Arabia: Can we change the way we deal with the disease? J Infect Public Health 2010;3(1):17-24
11. Langley J, Ellis E, Deeks S, National Advisory Committee on Immunization; Health Canada First Nations; Inuit Health Branch. Statement on Bacille Calmette Guerin (BCG) vaccine. Can Commun Dis Rep. 2004;30:ACS-5.
12. Szczuka I. Adverse event after BCG vaccination in Poland in the years 1994-1997.Pneumonol. Alergol. Pol.1999; 67: 208-16.
13. Pankowska A, Rozniecki J. Complications after BCG vaccination in the urban section of Lodz in the years 1994-5. Pneumonol. Alergol. Pol. 1997;65: 761-6
14. Award R. BCG Vaccine and post BCG Complications among Infant In Gaza strip1999. East Mediter Health J. 2001; 7(1?2): 221-220.
15. Benamar F, Loupi E. Misuse and or overdose of BCG vaccine: evaluation over a 4-year period. Therapie 2001; 56:739-42.
16. Mande R, Fillastre C, Rovillon A. BCG vaccination 1986: complications. London: Dawsons, 112-58.
17. Helmick CG, D'Souza AJ, Goddard N. An outbreak of severe BCG axillary lymphadenitis in Saint Lucia, 1982-83. West Indies Med J 1986;35:12-7.
18. Hooi LN, Athiyah SO. An outbreak of BCG related lymphadenitis in Malaysian infants. Med. J. Malaysia 1994;49: 327-35.
19. Stogmann W. BCG vaccination. Wien Med. Wochenschr. 1991; 141: 265-70.
20. Teo SS, Smeulders N, Shingadia DV . BCG vaccine-associated suppurative lymphadenitis. Vaccine. 2005 Apr 8;23(20):2676-9.
21. Lotte A, Wasz-Hockert O, Poisson N, Dumitrescu N, Verron M, Couvet E. BCG complications. Adv Tuberc Res 1984;21:107-93.
22. Daoud W. Control of an outbreak of BCG complications in Gaza. Respirology. 2003 Sep;8(3):376-8.
23. Vitkova E, Galliova J, Krepela K, Kubin M. Adverse reactions to BCG . Cent. Eur. J. Public Health 1995;3:138-41.
24. Teulieres L, Diouf MA, Chaud P, Saint-Cyr A, Saliou P. Comparative trial of administration of half (0.05 mg) and quarter (0.025 mg) dose of intradermal Pasteur BCG on 291 infants from birth to 1 year in French Guyana. Vaccine 1991;9: 521-4.
25. Lotte A, Wasz-Hockert O, Poisson N, Engbaek H, Landmann H, Quast U, Andrasofszky B, Lugosi L, Vadasz I, Mihailescu P, et al. Second IU ATLD study on complications induced by intradermal BCG -vaccination. Bull Int Union Tuberc Lung Dis 1988; 63(2):47-59.
26. Kuyucu N, Kuyucu S, Ocal B, Tezic T. Comparison of oral erythromycin, local administration of streptomycin and placebo therapy for nonsuppurative Bacillus Calmette-Guerin lymphadenitis. Pediatr Infect Dis J 1998; 17(6):524-5.